Literature DB >> 6406781

Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels.

J A Clemens, D R Bennett, L J Black, C D Jones.   

Abstract

Keoxifene (LY156758) is a new benzothiophene-derived antiestrogen with an extremely low degree of estrogenicity. Administration of 1-20 mg/kg per day inhibited the growth of 7, 12-dimethylbenzanthracene (DMBA)-induced mammary tumors in rats. The degree of inhibition of mammary tumor growth was similar to that observed with tamoxifen treatment.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6406781     DOI： 10.1016/0024-3205(83)90323-5

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  19 in total

Review 1.  Effect of SERMs on the uterus and menopausal symptoms.

Authors:  M Dören
Journal:  J Endocrinol Invest       Date:  1999-09       Impact factor: 4.256

Review 2.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

Review 3.  Selective estrogen receptor modulators.

Authors:  Henry U Bryant
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

Review 4.  The estrogen receptor: a logical target for the prevention of breast cancer with antiestrogens.

Authors:  D A Tonetti; V C Jordan
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 5.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

6.  Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.

Authors:  Gregor M Balaburski; Rita C Dardes; Michael Johnson; Bassem Haddad; Fang Zhu; Eric A Ross; Surojeet Sengupta; Andres Klein-Szanto; Hong Liu; Eun Sook Lee; Helen Kim; V Craig Jordan
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

7.  Flexible small molecular anti-estrogens with N,N-dialkylated-2,5-diethoxy-4-morpholinoaniline scaffold targets multiple estrogen receptor conformations.

Authors:  Bethany K Asare; Emmanuel Yawson; Rajendram V Rajnarayanan
Journal:  Cell Cycle       Date:  2017-07-19       Impact factor: 4.534

8.  Effects of progesterone (P) and antiprogestin RU486 on LH and FSH release by incubated pituitaries from rats treated with the SERM LY11701 8-HCl and/or recombinant human FSH.

Authors:  C Bellido; R Aguilar; J C Garrido-Gracia; J E Sánchez-Criado
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

9.  Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer.

Authors:  Masa-Aki Shibata; Junji Morimoto; Eiko Shibata; Hitomi Kurose; Kanako Akamatsu; Zhong-Lian Li; Moriaki Kusakabe; Masahide Ohmichi; Yoshinori Otsuki
Journal:  BMC Cancer       Date:  2010-10-19       Impact factor: 4.430

10.  Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line.

Authors:  R Poulin; D Baker; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1988-10       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.